{"id":"baricitinib-oral-tablet","safety":{"commonSideEffects":[{"rate":"15–20","effect":"Upper respiratory tract infection"},{"rate":"10–15","effect":"Elevated cholesterol"},{"rate":"5–10","effect":"Herpes zoster reactivation"},{"rate":"5–10","effect":"Elevated liver enzymes"},{"rate":"5–8","effect":"Headache"},{"rate":"3–5","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Baricitinib selectively inhibits JAK1 and JAK2 enzymes, which are intracellular kinases involved in the signaling of multiple inflammatory cytokines including interferons and interleukins. By blocking JAK-STAT pathway signaling, the drug suppresses the proliferation and activation of immune cells, reducing systemic inflammation and autoimmune responses. This mechanism makes it effective in conditions driven by dysregulated Th1 and Th17 cell responses.","oneSentence":"Baricitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:33.062Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Atopic dermatitis"},{"name":"Alopecia areata"},{"name":"COVID-19 (investigational)"}]},"trialDetails":[{"nctId":"NCT07262983","phase":"PHASE1","title":"Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES","enrollment":20},{"nctId":"NCT06631287","phase":"PHASE3","title":"Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID","status":"RECRUITING","sponsor":"Wes Ely","startDate":"2024-10-21","conditions":"Long COVID, Sars-CoV-2 Infection, Coronavirus Infections","enrollment":550},{"nctId":"NCT07222332","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-05","conditions":"Diabetes Mellitus, Type 1","enrollment":300},{"nctId":"NCT07491016","phase":"","title":"Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2026-03-01","conditions":"Telitacicept, Treatment Compliance, Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT05524311","phase":"PHASE2","title":"Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-10","conditions":"Juvenile Dermatomyositis","enrollment":16},{"nctId":"NCT05452564","phase":"PHASE2","title":"Baricitinib for Reduction of HIV - CNS","status":"RECRUITING","sponsor":"William Tyor","startDate":"2023-05-18","conditions":"Human Immunodeficiency Virus","enrollment":95},{"nctId":"NCT06158113","phase":"PHASE2","title":"Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-03-13","conditions":"Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus","enrollment":10},{"nctId":"NCT07222137","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-01-12","conditions":"Diabetes Mellitus, Type 1","enrollment":150},{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT05016297","phase":"PHASE2","title":"Efficacy and Safety of Baricitinib in Sjogren's Syndrome","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-14","conditions":"Sjogren's Syndrome","enrollment":87},{"nctId":"NCT07448363","phase":"","title":"Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","status":"NOT_YET_RECRUITING","sponsor":"Caja Costarricense de Seguro Social","startDate":"2026-05","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)","enrollment":50},{"nctId":"NCT07449910","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2026-03-17","conditions":"Acute Ichemic Stroke, Anterior Cerebral Artery Stroke, Baricitinib","enrollment":750},{"nctId":"NCT06923072","phase":"PHASE2","title":"Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2026-02-18","conditions":"Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease","enrollment":12},{"nctId":"NCT07028385","phase":"PHASE2","title":"Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-09-22","conditions":"HIV","enrollment":30},{"nctId":"NCT07209267","phase":"PHASE2","title":"Baricitinib Curative Repression of HIV-1","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"HIV Infection, HIV","enrollment":20},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT05723198","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-02-27","conditions":"Areata Alopecia, Alopecia, Hypotrichosis","enrollment":595},{"nctId":"NCT04088396","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-02-12","conditions":"Systemic Juvenile Idiopathic Arthritis","enrollment":58},{"nctId":"NCT05651880","phase":"PHASE3","title":"Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-03","conditions":"Active Non-anterior Non-infectious Uveitis","enrollment":33},{"nctId":"NCT03773965","phase":"PHASE3","title":"A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-04-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":190},{"nctId":"NCT06868381","phase":"PHASE2","title":"A Trial of Baricitinib in Patients With Cardiac Sarcoidosis","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-04-01","conditions":"Cardiac Sarcoidosis","enrollment":10},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT06240351","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2024-04-22","conditions":"Frontal Fibrosing Alopecia","enrollment":15},{"nctId":"NCT05300932","phase":"PHASE4","title":"A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-03-08","conditions":"Systemic Sclerosis","enrollment":60},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT07357649","phase":"PHASE4","title":"Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-01","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT05189106","phase":"PHASE1, PHASE2","title":"Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2022-12-05","conditions":"Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment","enrollment":17},{"nctId":"NCT03921554","phase":"PHASE2","title":"JAK Inhibitor Treatment in AGS","status":"COMPLETED","sponsor":"Adeline Vanderver, MD","startDate":"2019-06-03","conditions":"Aicardi Goutieres Syndrome","enrollment":54},{"nctId":"NCT06490757","phase":"PHASE2","title":"A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-10-02","conditions":"Inflammatory Hepatocellular Adenoma","enrollment":25},{"nctId":"NCT05074420","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Children With COVID-19","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2021-12-21","conditions":"Covid19, Corona Virus Infection","enrollment":6},{"nctId":"NCT05969730","phase":"NA","title":"Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2023-08-15","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT07279688","phase":"PHASE3","title":"Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-12-12","conditions":"Polymyalgia Rheumatica (PMR)","enrollment":140},{"nctId":"NCT07268534","phase":"PHASE2","title":"Biologics in Folliculitis Decalvans : an Adaptative Trial Research","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-01","conditions":"Folliculitis Decalvans (FD)","enrollment":120},{"nctId":"NCT05955066","phase":"PHASE4","title":"Effect of JAK Inhibitor on Erosion Healing in RA","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-12-01","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT05379322","phase":"PHASE3","title":"The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Abu Dhabi Stem Cells Center","startDate":"2023-03-01","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT03570749","phase":"PHASE2, PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-09-24","conditions":"Alopecia Areata","enrollment":764},{"nctId":"NCT07003997","phase":"PHASE2","title":"JAK Signaling in Depression","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-03","conditions":"Major Depressive Disorder","enrollment":100},{"nctId":"NCT06737705","phase":"PHASE2","title":"Baricitinib for Respiratory Injury in Patients With Intracerebral Hemorrhage","status":"COMPLETED","sponsor":"De-zhi Kang","startDate":"2025-01-01","conditions":"Intracerebral Hemorrhage, Acute Lung Injury(ALI)","enrollment":110},{"nctId":"NCT04972760","phase":"PHASE3","title":"Baricitinib in Patients With Relapsing or naïve Dermatomyositis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-08-31","conditions":"Dermatomyositis","enrollment":62},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT07081763","phase":"PHASE2","title":"Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2026-05","conditions":"HIV-1-infection","enrollment":191},{"nctId":"NCT03915964","phase":"PHASE4","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-25","conditions":"Rheumatoid Arthritis","enrollment":2663},{"nctId":"NCT03358693","phase":"","title":"Molecular Signatures in Inflammatory Skin Disease","status":"RECRUITING","sponsor":"Prof. Dr. Stephan Weidinger","startDate":"2017-01-20","conditions":"Atopic Dermatitis, Psoriasis","enrollment":300},{"nctId":"NCT04692493","phase":"PHASE3","title":"RA-PRO PRAGMATIC TRIAL","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Rheumatoid Arthritis","enrollment":924},{"nctId":"NCT04086745","phase":"PHASE4","title":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-14","conditions":"Rheumatoid Arthritis","enrollment":1317},{"nctId":"NCT04517253","phase":"PHASE2, PHASE3","title":"A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2020-10-27","conditions":"Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy","enrollment":10},{"nctId":"NCT06065046","phase":"PHASE2","title":"Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2023-11-24","conditions":"Traumatic Brain Injury","enrollment":100},{"nctId":"NCT05849038","phase":"PHASE2","title":"Inflammation and Depression in People With HIV","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-12-11","conditions":"HIV, Depression, Anhedonia","enrollment":60},{"nctId":"NCT06977035","phase":"NA","title":"Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-05","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT05852171","phase":"PHASE2","title":"Baricitinib in Idiopathic Granulomatous Mastitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-05-04","conditions":"Mastitis Chronic, Idiopathic Granulomatous Mastitis","enrollment":20},{"nctId":"NCT04901325","phase":"PHASE2","title":"Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2023-10-03","conditions":"Pyoderma Gangrenosum, Skin Diseases, Wound Heal","enrollment":5},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT03952559","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-05-24","conditions":"Atopic Dermatitis","enrollment":516},{"nctId":"NCT06936215","phase":"PHASE3","title":"Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2024-01-01","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":24},{"nctId":"NCT04088409","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-10-16","conditions":"Uveitis","enrollment":30},{"nctId":"NCT03549416","phase":"","title":"BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2018-01-01","conditions":"Atopic Dermatitis","enrollment":1200},{"nctId":"NCT06898372","phase":"","title":"Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome","status":"COMPLETED","sponsor":"IRCCS Fondazione Stella Maris","startDate":"2024-04-07","conditions":"Aicardi-Goutières Syndrome (AGS)","enrollment":24},{"nctId":"NCT05237388","phase":"PHASE2","title":"Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease","status":"RECRUITING","sponsor":"Duke University","startDate":"2023-04-20","conditions":"Chronic Kidney Diseases","enrollment":75},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT06849908","phase":"PHASE2","title":"Baricitinib in the Treatment of Intestinal Behçet's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-11-08","conditions":"Behcet Syndrome, Intestinal Type","enrollment":56},{"nctId":"NCT05099315","phase":"","title":"Microbiome in Atopic Dermatitis Under Systemic Therapy","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2019-10-01","conditions":"Atopic Dermatitis","enrollment":600},{"nctId":"NCT05858515","phase":"PHASE3","title":"REVERSE-Long COVID-19 With Baricitinib Study","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2024-10-21","conditions":"Post-Acute COVID-19 Syndrome","enrollment":""},{"nctId":"NCT03899259","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-07-08","conditions":"Alopecia Areata","enrollment":546},{"nctId":"NCT06797310","phase":"PHASE2","title":"Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-01-23","conditions":"Alopecia Areata","enrollment":30},{"nctId":"NCT01724580","phase":"","title":"Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes","status":"APPROVED_FOR_MARKETING","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)","enrollment":""},{"nctId":"NCT06768294","phase":"PHASE2","title":"Baricitinib in CPPD - the BAPTIST Study","status":"NOT_YET_RECRUITING","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2025-01","conditions":"Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis","enrollment":32},{"nctId":"NCT06768840","phase":"PHASE2, PHASE3","title":"Vitiligo, New Treatment and Serum s100B","status":"RECRUITING","sponsor":"South Valley University","startDate":"2024-10-02","conditions":"Vitiligo, Generalized","enrollment":50},{"nctId":"NCT04084223","phase":"NA","title":"JAKPOT (JAK Inhibitors and Predictors of Outcome in RheumaToid Arthritis)","status":"TERMINATED","sponsor":"University Hospital, Montpellier","startDate":"2019-10-10","conditions":"Rheumatoid Arthritis","enrollment":51},{"nctId":"NCT04774224","phase":"PHASE2","title":"Baricitinib in New-onset Type 1 Diabetes","status":"COMPLETED","sponsor":"St Vincent's Institute of Medical Research","startDate":"2020-10-30","conditions":"Type 1 Diabetes","enrollment":91},{"nctId":"NCT06687551","phase":"PHASE4","title":"JAK Inhibitor Dose TAPering Strategy Study","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2025-01-01","conditions":"Rhumatoid Arthisis","enrollment":308},{"nctId":"NCT06662721","phase":"PHASE2","title":"Baricitinib for Refractory Takayasu Arteritis","status":"COMPLETED","sponsor":"Liu Tian","startDate":"2023-04-03","conditions":"Takayasu Arteritis","enrollment":10},{"nctId":"NCT05792462","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2023-04-15","conditions":"NMO Spectrum Disorder","enrollment":12},{"nctId":"NCT02759731","phase":"PHASE1, PHASE2","title":"Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-11-01","conditions":"Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease","enrollment":24},{"nctId":"NCT05897372","phase":"PHASE2","title":"Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study","status":"TERMINATED","sponsor":"Iain Bressendorff","startDate":"2023-08-01","conditions":"Diabetic Kidney Disease","enrollment":1},{"nctId":"NCT05638932","phase":"","title":"Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments","status":"COMPLETED","sponsor":"Aetion, Inc.","startDate":"2020-06-16","conditions":"COVID-19","enrollment":1442},{"nctId":"NCT03334435","phase":"PHASE3","title":"A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-28","conditions":"Atopic Dermatitis","enrollment":1645},{"nctId":"NCT06573593","phase":"","title":"Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-07-29","conditions":"Alopecia Areata, Janus Kinase Inhibitors","enrollment":150},{"nctId":"NCT06475820","phase":"PHASE2, PHASE3","title":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2023-12-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia","enrollment":150},{"nctId":"NCT06558305","phase":"","title":"IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-09","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT06548802","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2024-02-29","conditions":"Pulmonary Injury After Intracerebral Hemorrhage","enrollment":100},{"nctId":"NCT06545110","phase":"PHASE1","title":"Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"South Valley University","startDate":"2023-09-01","conditions":"Alopecia Areata","enrollment":120},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05188521","phase":"PHASE2","title":"Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus","status":"COMPLETED","sponsor":"Aaron R. Mangold","startDate":"2022-01-11","conditions":"Cutaneous Lichen Planus","enrollment":12},{"nctId":"NCT06439615","phase":"PHASE2","title":"Baricitinib for the Lung Injury Following Spontaneous SAH","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-08-01","conditions":"Spontaneous Subarachnoid Hemorrhage","enrollment":100},{"nctId":"NCT05003310","phase":"NA","title":"ConsideRAte Study - Splenic Stimulation for RA","status":"RECRUITING","sponsor":"Galvani Bioelectronics","startDate":"2021-10-19","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT03428100","phase":"PHASE3","title":"A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-05-15","conditions":"Atopic Dermatitis","enrollment":463},{"nctId":"NCT03670069","phase":"PHASE1","title":"Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-09-30","conditions":"Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma","enrollment":27},{"nctId":"NCT01965132","phase":"","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2012-12-01","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":10000},{"nctId":"NCT06366932","phase":"PHASE4","title":"Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models","status":"RECRUITING","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2023-09-25","conditions":"Atopic Dermatitis","enrollment":150},{"nctId":"NCT04970719","phase":"PHASE3","title":"Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2021-07-10","conditions":"COVID-19 Pneumonia","enrollment":""},{"nctId":"NCT04890626","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19","status":"COMPLETED","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2020-04-04","conditions":"SARS-CoV-2 Infection","enrollment":356},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT06114407","phase":"PHASE2","title":"Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-10-30","conditions":"Spondyloarthritis, Axial","enrollment":184},{"nctId":"NCT03945760","phase":"EARLY_PHASE1","title":"Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Wright State Physicians","startDate":"2020-09-14","conditions":"Allergic Contact Dermatitis","enrollment":23},{"nctId":"NCT05082714","phase":"NA","title":"Tocilizumab Versus Baricitinib in Patients With Severe COVID-19","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2021-10-20","conditions":"COVID-19","enrollment":251},{"nctId":"NCT04027101","phase":"PHASE2","title":"BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2020-12-01","conditions":"Polymyalgia Rheumatic (PMR)","enrollment":34},{"nctId":"NCT05238896","phase":"PHASE4","title":"BARIcitinib Cognitive Emotional and Neural signaTuRE","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-27","conditions":"Rheumatoid Arthritis","enrollment":5},{"nctId":"NCT05660655","phase":"PHASE4","title":"Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2022-10-01","conditions":"Rheumatoid Arthritis","enrollment":94},{"nctId":"NCT05263505","phase":"PHASE2","title":"Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2022-02-21","conditions":"Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis","enrollment":2},{"nctId":"NCT05112120","phase":"","title":"Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2021-07-21","conditions":"Rheumatoid Arthritis","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY3009104","Olumiant","Arm B"],"phase":"phase_3","status":"active","brandName":"Baricitinib Oral Tablet","genericName":"Baricitinib Oral Tablet","companyName":"Azienda Ospedaliero, Universitaria Pisana","companyId":"azienda-ospedaliero-universitaria-pisana","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baricitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation. Used for Rheumatoid arthritis, Atopic dermatitis, Alopecia areata.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}